TBWA
ACRS icon

Three Bridge Wealth Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Three Bridge Wealth Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.68M Hold
714,823
– – 0.74% 22
2025
Q4 		$2.15M Hold
714,823
– – 0.57% 27
2025
Q3 		$1.36M Buy
+714,823
New +$1.25M 0.35% 35

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Three Bridge Wealth Advisors's ACRS Position: Q1 2026 in Review

Three Bridge Wealth Advisors held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 714,823 shares worth $2.68M. The position accounts for 0.74% of the portfolio, ranked #22.

Three Bridge Wealth Advisors first reported a position in ACRS in Q3 2025 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Three Bridge Wealth Advisors held 714,823 shares of Aclaris Therapeutics worth $2.68M as of Q1 2026.
  • Three Bridge Wealth Advisors left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up 0.74% of Three Bridge Wealth Advisors's portfolio in Q1 2026, its #22 holding.
  • Three Bridge Wealth Advisors first reported a position in Aclaris Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Three Bridge Wealth Advisors's 13F filing for Q1 2026, filed 12 May 2026.